Pericarditis is a condition of swelling and irritation of the pericardium sac which may cause chest pain, heart palpitations and others. Chest pain in pericarditis occurs when the irritated layers of the pericardium rub against each other. The pericarditis is classified by type as acute, chronic and recurrent pericarditis. Acute pericarditis begins suddenly and does not last long whereas chronic pericarditis occurs when the symptoms develop more gradually and persist for long duration of weeks to months. Most of the pericarditis cases are acute and they improve on their own. However, sometimes the treatment for chronic cases may include medication and surgery. According to the studies conducted by the American Heart Association growing geriatric population is more susceptible to pericarditis. Moreover, it is estimated that 15% to 30% of the patients who have been treated for pericarditis can again develop the condition. According to the World Health Organization, geriatric population of the U.S. is expected reach 98 million by 2060. This growing geriatric population, increasing prevalence of cardiovascular diseases and rising healthcare are the main drivers for the market growth. However, lack of awareness and low per capita healthcare expenditure in the developing countries may restrain the market growth during the forecast period.
Get a sample report at https://www.marketresearchfuture.com/sample_request/1847 .
Key players for global pericarditis market
The key players for the global pericarditis market are Pfizer Inc. (U.S.), AstraZeneca (U.S.), Bayer AG (Europe), Reckitt Benckiser Group plc. (Europe), PerkinElmer, Inc. (U.S.), FUJIFILM Holdings Corporation (Asia Pacific), Merck Sharp & Dohme Corp. (U.S.), ALLERGAN (Europe), and others
America dominates the global pericarditis market. Increasing healthcare expenditure, rising patient population for the cardiovascular diseases and growing geriatric population drives the growth of the market in America. In 2015, according to the Centres for Disease Control and Prevention, in the U.S. the total healthcare expenditure accounted for 17.8% of the total gross domestic product (GDP), which accounted for USD 3.2 trillion.
Europe is the second largest pericarditis market, which is followed by Asia Pacific. Availability of funds for research, huge patient population, increasing healthcare expenditures drives the market growth within the region. Moreover, a well-developed healthcare sector and increasing government support for research & development are projected to fuels the market growth. Regionally, Europe is divided into Western Europe and Eastern Europe. Western Europe holds a major share of the regional market, which is majorly contributed by Germany, the U.K., and France. However, Eastern Europe is the fastest growing region due the huge opportunities in the untapped market.
Asia Pacific is the fastest growing region in global the market due to the presence of continuously developing economies like India and China. Moreover, increasing demands for the healthcare services followed by increasing geriatric population and increasing healthcare expenditures fuels the market. According to Indian Brand Equity Foundation in 2017, the Indian healthcare sector is estimated as one of the fastest growing industries in India and is expected to reach a net worth of USD 280 billion by 2020.
On the other hand, the Middle East & Africa holds the least share in the global pericarditis market due to presence of poor economy, especially, in African region. Majority of the market of this region is held by the Middle East due to a well-developed healthcare sector and huge healthcare expenditure.
Browse complete report at https://www.marketresearchfuture.com/reports/pericarditis-market-1847 .
The global pericarditis market is segmented on the basis of type, diagnosis, treatment, and end users.
On the basis of type, the market is segmented into acute, chronic, recurrent pericarditis, and others.
On the basis of diagnosis, the market is segmented into electrocardiogram, echocardiogram, X-ray blood test, and others. The electrocardiogram segment, is sub segmented into EKG, ECG, and others. The echocardiogram segment is sub segmented into transthoracic echocardiogram, transesophageal echocardiogram, stress echocardiogram, and others.
On the basis of treatment, the market is segmented into pharmacologic, surgical, and others. The pharmacologic segment is further segmented into non-steroidal anti-inflammatory drugs (NSAIDs), colchicine, and others. The NSAIDs segment is sub segmented into aspirin, ibuprofen, and others. The surgical segment is sub-segmented into pericardiectomy, pericardiocentesis, pericardiotomy, and others.
On the basis of end users, the market is segmented into hospitals & clinics, medical institutes, research organization, and others.
LIST OF FIGURES
Figure 1 Research Process
Figure 2 Segmentation For Global Pericarditis Market
Figure 3 Market Dynamics For Global Pericarditis Market
Figure 4 Global Pericarditis Market Share, By Type 2016
Figure 5 Global Pericarditis Market Share, By Diagnosis 2016
Figure 6 Global Pericarditis Market Share, By Treatment, 2016
Figure 7 Global Pericarditis Market Share, By End Users, 2016
Figure 8 Global Pericarditis Market Share, By Region, 2016
Market Research Future
Magarpatta Road, Hadapsar,
Pune – 411028
+1 646 845 9312